Tiziana Life Sciences PLC Stock News

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced it has received non-dilutive funding of $3.4 million which will be used to advance its investigation therapy foralumab. The company highlighted that f

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerat

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has won approval from the US Food and Drug Administration under an Expanded Access IND to dose its first patient with moderate Alzheimer's dis

NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies

Tiziana Life Sciences Ltd (NASDAQ:TLSA), said it is seeking Fast Track Designation approval from the US Food and Drug Administration (FDA) for its intranasal foralumab therapy to treat non-active, sec

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled encouraing results from patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS) enrolled in its Expanded Access Program who hav

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it along with its research partners at Mass General Hospital have been invited to apply for a prestigious grant from the ALS Association to fund

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the Chairman of its Scientific Advisory Board, Howard L  Weiner, is to receive the “Giants of MS” award. The award ceremony will be held on May 30, 2

NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies v

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has requested its multiple sclerosis treatment be granted orphan drug designation by the Food and Drug Administration (FDA). Tiziana's intranasal foralumab wo

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies v

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled new neuroimaging data which shows its investigational drug intranasal foralumab improved White Matter Z-scores in patients with non-secondary progr

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been approved by the US Food and Drug Administration to expand patient enrollment in its non-active Secondary Progressive Multiple Scleros

NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies